Provided by Tiger Trade Technology Pte. Ltd.

Sutro Biopharma Inc

15.52
+0.92006.30%
Post-market: 15.44-0.0806-0.52%17:44 EST
Volume:108.98K
Turnover:1.69M
Market Cap:132.22M
PE:-0.60
High:16.24
Open:14.85
Low:14.27
Close:14.60
52wk High:21.20
52wk Low:5.23
Shares:8.52M
Float Shares:6.10M
Volume Ratio:1.21
T/O Rate:1.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-25.8759
EPS(LYR):-29.6061
ROE:-1810.01%
ROA:-25.80%
PB:-1.52
PE(LYR):-0.52

Loading ...

Sutro Biopharma Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Jan 20

Sutro Biopharma upgraded to Outperform from Market Perform at Citizens

TIPRANKS
·
Jan 20

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO) and Molina Healthcare (MOH)

TIPRANKS
·
Jan 16

Sutro Biopharma Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025

Sutro Biopharma Inc : H.c. Wainwright Raises Target Price to $10 From $2

THOMSON REUTERS
·
Dec 22, 2025

Sutro Biopharma Completes 1-for-10 Reverse Stock Split

Reuters
·
Dec 18, 2025

Sutro Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
Dec 18, 2025

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 17, 2025

Sutro Biopharma Enacts 1-for-10 Reverse Stock Split

Reuters
·
Dec 04, 2025

BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004

Reuters
·
Dec 03, 2025

Sutro Biopharma Doses First Patients in Phase 1 Trial of STRO-004 for TF-Expressing Solid Tumors

Reuters
·
Dec 03, 2025

Sutro Biopharma Inc - Initial Clinical Data Expected Mid-2026

THOMSON REUTERS
·
Dec 03, 2025

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of Stro-004, a Next-Generation Tissue Factor ADC, in Tf-Expressing Solid Tumors

THOMSON REUTERS
·
Dec 03, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

Reuters
·
Dec 03, 2025

BRIEF-Sutro Biopharma Announces 1-For-10 Reverse Stock Split

Reuters
·
Dec 01, 2025

Sutro Biopharma Q3 Revenue USD 9.693 Million

Reuters
·
Nov 20, 2025

Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7

Reuters
·
Nov 12, 2025

Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL), Doximity (DOCS) and Sutro Biopharma (STRO)

TIPRANKS
·
Nov 11, 2025

Sutro Biopharma Q3 revenue rises,  extends cash runway to mid-2027

Reuters
·
Nov 07, 2025

Sutro Biopharma Q3 EPS $(0.67) Misses $(0.41) Estimate, Sales $9.693M Beat $9.132M Estimate

Benzinga
·
Nov 07, 2025